GlassScriptPhysician profile
Meghan E Wooster
NPI 1710305628
$1,188.28
in general payments reported to CMS, 2019-2025
15 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $242 · 2021: $18.31 · 2022: $190 · 2023: $98.58 · 2024: $42.68 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414 · Travel and Lodging: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.55 |
| Travel and Lodging | $204.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $482.46 | 2019-2025 | |
| Medical Device Business Services, INC. | $209.68 | 2020 | |
| Ethicon US, LLC | $141.37 | 2019-2023 | Dermabond Prineo, Harmonic, Endopath Xcel |
| Organogenesis INC. | $112.50 | 2022 | |
| Abbvie INC. | $50.52 | 2023-2025 | Dalvance |
| Elucent Medical | $30.61 | 2025 | |
| Kerecis Limited | $25.33 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Polynovo North America LLC | $19.71 | 2020 | |
| Medtronic, INC. | $19.23 | 2023 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $18.61 | 2025 | Voquezna |
| Csl Behring | $18.31 | 2021 | |
| Tela Bio, INC. | $17.35 | 2024 | Ovitex 2s |
| Mesh Suture INC | $16.55 | 2025 | |
| Davol INC. | $13.66 | 2025 | Phasix Mesh |
| Z-Medica, LLC | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Wooster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.